DaVita Inc. (DVA)

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

Ticker
DVA
Exchange
NYSE
Sector
Healthcare
Industry
Medical Care Facilities
Market cap
$10.26B
52-week range
$101.00 - $247.49

Valuation

Share price
$161.79 (close of Nov 18, 2026)
P/E (TTM)
11.65x
Price to book
-28.61x
Price to free cash flow
7.93x
Enterprise value
$23.15B
Book value per share
$-5.65

Price performance

PeriodChange
1 day-6.48%
5 days-11.83%
1 month-13.62%
3 months-9.06%
6 months-18.91%
Year to date+42.41%
1 year+38.80%
3 years+68.25%
5 years+59.15%
10 years+162.99%
All time+3,870.31%

Short interest

As of
Oct 30, 2026
Short % of float
16.30%
Shares short
5.14M
Days to cover
5.14
Change since prior report
+4.82%
Source
FINRA consolidated short interest

Members of Congress who disclosed DVA trades

Julie Johnson · Alan Armstrong

Super investors holding DVA

Warren Buffett (Berkshire Hathaway) · Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates)

Profitability and growth

Return on invested capital
14.00%
Return on assets
4.27%
Return on capital employed
14.25%
Gross margin
27.25%
Net margin
5.47%
EBITDA margin
20.22%
Revenue growth
6.46%
Net income growth
-20.24%
Free cash flow growth
-10.63%

Cash flow and balance sheet

Free cash flow yield (TTM)
12.61%
Current ratio
1.41x
Net debt to EBITDA
4.59x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$13.64B
Cost of revenue
$9.93B
Gross profit
$3.72B
EBITDA
$2.76B
Net income
$746.80M
Earnings per share
$10.06
Interest expense
$579.93M
Shares outstanding
74.23M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$13.64B$3.72B$746.80M$10.06
2024-12-31$12.82B$3.63B$936.34M$11.02
2023-12-31$12.14B$3.08B$691.53M$7.62
2022-12-31$11.61B$2.69B$560.40M$6.03
2021-12-31$11.62B$2.99B$978.45M$9.30
2020-12-31$11.55B$2.94B$773.64M$6.46
2019-12-31$11.39B$2.75B$810.98M$5.29
2018-12-31$11.40B$2.66B$159.39M$0.93
2017-12-31$10.88B$2.88B$663.62M$3.52
2016-12-31$10.71B$3.10B$879.87M$4.36

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3127.25%5.47%-14.00%
2024-12-3128.32%7.31%-14.53%
2023-12-3125.34%5.70%55.59%11.19%
2022-12-3123.21%4.83%63.98%8.99%
2021-12-3125.76%8.42%104.52%11.55%
2020-12-3125.47%6.70%49.38%10.82%
2019-12-3124.12%7.12%34.97%10.11%
2018-12-3123.33%1.40%4.08%9.05%
2017-12-3126.45%6.10%13.58%10.47%
2016-12-3128.98%8.22%18.14%11.45%

Cash and debt by year

Period endCashDebt
2025-12-31$676.44M$10.16B
2024-12-31$794.93M$9.18B
2023-12-31$380.06M$8.27B
2022-12-31$244.09M$8.69B
2021-12-31$461.90M$8.73B
2020-12-31$324.96M$7.92B
2019-12-31$1.10B$7.98B
2018-12-31$323.04M$8.17B
2017-12-31$509.43M$9.16B
2016-12-31$675.98M$8.94B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$1.31B$139.95M
2024-12-31$1.47B$102.79M
2023-12-31$1.49B$112.38M
2022-12-31$961.14M$95.43M
2021-12-31$1.29B$102.21M
2020-12-31$1.30B$91.46M
2019-12-31$1.31B$67.85M
2018-12-31$784.50M$73.06M
2017-12-31$1.01B$35.09M
2016-12-31$1.14B$38.34M

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-10-29Sep 2026$3.78
2026-08-04Jun 2026$4.01
2026-05-05Mar 2026$2.41
2026-02-02Dec 2025$3.24
2025-10-29Sep 2025$3.29
2025-08-05Jun 2025$2.70
2025-05-12Mar 2025$1.75
2025-04-30--

Filings and sources

Company website
davita.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Universal Health Services Inc (UHS) · HCA Healthcare, Inc. (HCA) · Abbott Laboratories (ABT) · HealthEquity, Inc. (HQY) · Medtronic plc (MDT) · Veeva Systems Inc (VEEV) · Stryker Corp (SYK) · Molina Healthcare, Inc. (MOH)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades